147963-99-3

Basic information

• Product Name: (1'-(4-fluorophenyl)(ethylenedioxy))-21-hydroxy-19-norpregn-4-ene-3,20-dione
• Synonyms: (1'-(4-fluorophenyl)(ethylenedioxy))-21-hydroxy-19-norpregn-4-ene-3,20-dione
• CAS NO: 147963-99-3
• Molecular Formula: C28H33 F O5
• Molecular Weight: 468.56
• Mol File: 147963-99-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 614.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.30±0.1 g/cm3(Predicted)
• PKA: 12.87±0.10(Predicted)
• CAS DataBase Reference: (1'-(4-fluorophenyl)(ethylenedioxy))-21-hydroxy-19-norpregn-4-ene-3,20-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (1'-(4-fluorophenyl)(ethylenedioxy))-21-hydroxy-19-norpregn-4-ene-3,20-dione(147963-99-3)
• EPA Substance Registry System: (1'-(4-fluorophenyl)(ethylenedioxy))-21-hydroxy-19-norpregn-4-ene-3,20-dione(147963-99-3)

Safety Data

• Hazardous Substances Data: 147963-99-3(Hazardous Substances Data)

Usage

General Description

"(1'-(4-fluorophenyl)(ethylenedioxy))-21-hydroxy-19-norpregn-4-ene-3,20-dione" is a synthetic chemical compound with a complex structure, containing a fluorophenyl group, an ethylenedioxy group, and a norpregn-4-ene-3,20-dione backbone. It is a derivative of the hormone progesterone and is used in the development of pharmaceutical drugs. The compound may have potential applications in the treatment of hormone-related conditions, such as reproductive disorders and certain types of cancer. Its precise mechanism of action and specific therapeutic uses would require further research and clinical trials. Due to its intricate structure and potential medical significance, "(1'-(4-fluorophenyl)(ethylenedioxy))-21-hydroxy-19-norpregn-4-ene-3,20-dione" is of interest to the pharmaceutical and medical research communities.

Upstream product

• 42224-77-1 21-hydroxy-19-norpregna-4,16-diene-3,20-dione 
• 734-32-7 estra-4-ene-3,17-dione 
• 434-22-0 19-nortestosterone 
• 403-42-9 1-(4-fluorophenyl)ethanone 
• 148022-19-9 16α,17α,21-trihydroxy-19-norpregn-4-ene-3,20-dione 

Relevant articles and documents

Fluorine-18-Labeled Progestin Ketals: Synthesis and Target Tissue Uptake Selectivity of Potential Imaging Agents for Receptor-Positive Breast Tumors

We have studied two new fluorine-substituted progestins as potential imaging agents for progesterone-receptor-positive human breast tumors. The steroids are 16α,17α-fluoroacetophenone ketals of 16α,17α-dihydroxyprogesterone and 16α,17α,21-trihydroxy-19-norprogesterone. Synthesis of the latter compound in seven steps from 19-norandrost-4-ene-3,17-dione is reported. Both compounds demonstrate high affinity for the progesterone receptor (PgR) (52.5 and 240percent, respectively, relative to R5020 = 100). The syntheses were adapted to 18F-labeling with 4'--fluoroacetophenone, prepared from 4'-nitroacetophenone by nucleophilic substitution with K18F/Kryptofix. Considerable adjustment of reaction conditions was required to effect ketalization using tracer quantities of the ketone. In tissue distribution studies in estrogen-primed immature female rats, both ketals showed selective uterine uptake, which was blocked by coinjection of a saturating dose of the unlabeled progestin ORG 2058. Additionally, metabolic stability of the radiolabel was indicated by the low radioactivity levels seen in bone. Both compounds showed relatively high uptake in fat, in accord with their relative lipophilicities demonstrated by HPLC-derived octanol-water partition coefficients. The selective uterine uptake and metabolic stability of these compounds suggests that this class of PgR ligands might be promising for the selective imaging of receptor-positive tumors if derivatives of reduced lipophilicity can be prepared.